Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα.

Horgan XJ, Tatum H, Brannan E, Paull DH, Rhodes LV.

Oncol Rep. 2019 Jun;41(6):3517-3526. doi: 10.3892/or.2019.7122. Epub 2019 Apr 16.

PMID:
31002359
2.

A Retrospective Cohort Study to Assess the Impact of an Inpatient Infectious Disease Telemedicine Consultation Service on Hospital and Patient Outcomes.

Monkowski D, Rhodes LV, Templer S, Kromer S, Hartner J, Pianucci K, Kincaid H.

Clin Infect Dis. 2019 Apr 19. pii: ciz293. doi: 10.1093/cid/ciz293. [Epub ahead of print]

PMID:
31002338
3.

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME.

BMC Cancer. 2019 Mar 7;19(1):205. doi: 10.1186/s12885-019-5401-2.

4.

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.

Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, Al-Khami AA, Hossain F, Riker AI, Rhodes LV, Martin EC, Miele L, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2018 Jun;169(2):381-390. doi: 10.1007/s10549-018-4685-2. Epub 2018 Feb 1.

5.

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.

Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME.

Noncoding RNA. 2016 Sep 21;2(3). pii: E8. doi: 10.3390/ncrna2030008.

6.

Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1.

Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM.

Oncogenesis. 2015 Oct 5;4:e168. doi: 10.1038/oncsis.2015.27.

7.

Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.

Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, Gimble JM, Burow ME, Bunnell BA.

Breast Cancer Res. 2015 Aug 19;17:112. doi: 10.1186/s13058-015-0622-z.

8.

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM.

Oncotarget. 2015 Jun 30;6(18):16638-52.

9.

Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma.

Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, Cohen EE, Onel K.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1222-8. doi: 10.1158/1055-9965.EPI-15-0275. Epub 2015 May 26.

10.

Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.

Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE, Boue SM, Burow ME.

J Steroid Biochem Mol Biol. 2015 Jun;150:17-23. doi: 10.1016/j.jsbmb.2014.12.014. Epub 2015 Mar 12.

11.

Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.

Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B.

Mol Carcinog. 2015 Dec;54(12):1656-67. doi: 10.1002/mc.22237. Epub 2014 Oct 18.

12.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

13.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9.

14.

Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways.

Strong AL, Strong TA, Rhodes LV, Semon JA, Zhang X, Shi Z, Zhang S, Gimble JM, Burow ME, Bunnell BA.

Breast Cancer Res. 2013;15(5):R102.

15.

MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.

16.

A new method for stranded whole transcriptome RNA-seq.

Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KP.

Methods. 2013 Sep 15;63(2):126-34. doi: 10.1016/j.ymeth.2013.03.023. Epub 2013 Apr 1.

17.

In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models.

Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J.

J Health Care Poor Underserved. 2013 Feb;24(1 Suppl):104-11. doi: 10.1353/hpu.2013.0047.

18.

Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer.

Tilghman SL, Rhodes LV, Bratton MR, Carriere P, Preyan LC, Boue SM, Vasaitis TS, McLachlan JA, Burow ME.

J Health Care Poor Underserved. 2013 Feb;24(1 Suppl):36-46. doi: 10.1353/hpu.2013.0036. Review.

19.

Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.

Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP, Burow ME.

Int J Oncol. 2013 Apr;42(4):1139-50. doi: 10.3892/ijo.2013.1814. Epub 2013 Feb 8.

20.

Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.

Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME.

PLoS One. 2012;7(11):e49067. doi: 10.1371/journal.pone.0049067. Epub 2012 Nov 30.

21.

Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.

Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME.

Mol Carcinog. 2014 Jan;53(1):38-48. doi: 10.1002/mc.21946. Epub 2012 Aug 21.

22.

Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME.

Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.

23.

Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Rhodes LV, Tilghman SL, Boue SM, Wang S, Khalili H, Muir SE, Bratton MR, Zhang Q, Wang G, Burow ME, Collins-Burow BM.

Oncol Lett. 2012 Jan;3(1):163-171. Epub 2011 Oct 24.

24.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

25.

Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.

Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G.

Breast Cancer Res. 2012 Mar 14;14(2):R45.

26.

Endocrine disruptor regulation of microRNA expression in breast carcinoma cells.

Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, Nephew KP, Burow ME.

PLoS One. 2012;7(3):e32754. doi: 10.1371/journal.pone.0032754. Epub 2012 Mar 5.

27.

Glyceollin-elicited soy protein consumption induces distinct transcriptional effects as compared to standard soy protein.

Wood CE, Boue SM, Collins-Burow BM, Rhodes LV, Register TC, Cline JM, Dewi FN, Burow ME.

J Agric Food Chem. 2012 Jan 11;60(1):81-6. doi: 10.1021/jf2034863. Epub 2011 Dec 19.

28.

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.

Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM.

Oncol Rep. 2012 Jan;27(1):10-6. doi: 10.3892/or.2011.1488. Epub 2011 Oct 4.

29.

Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.

Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME.

Exp Cell Res. 2011 Nov 1;317(18):2573-81. doi: 10.1016/j.yexcr.2011.08.016. Epub 2011 Aug 30.

30.

Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.

Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS.

J Mol Endocrinol. 2011 Apr 28;46(3):205-16. doi: 10.1530/JME-10-0116. Print 2011 Jun.

31.

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.

Cancer Res. 2011 Jan 15;71(2):603-13. doi: 10.1158/0008-5472.CAN-10-3185. Epub 2010 Dec 1. Erratum in: Cancer Res. 2011 May 1;71(9):3432.

32.

Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME.

Mol Cancer. 2010 Nov 18;9:295. doi: 10.1186/1476-4598-9-295.

33.

Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS.

Endocrinology. 2010 Nov;151(11):5124-35. doi: 10.1210/en.2010-0420. Epub 2010 Sep 22.

34.

Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.

Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, Wang G.

J Med Chem. 2010 Aug 26;53(16):6153-63. doi: 10.1021/jm100610w.

35.

Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression.

Rhodes LV, Burow ME.

ScientificWorldJournal. 2010 Jun 15;10:1084-7. doi: 10.1100/tsw.2010.108. No abstract available.

36.

Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence.

Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME.

Breast Cancer Res Treat. 2010 Jun;121(2):293-300. doi: 10.1007/s10549-009-0458-2. Epub 2009 Jul 12.

37.

Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation.

Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA.

Endocrinology. 2009 May;150(5):2436-45. doi: 10.1210/en.2008-0224. Epub 2009 Jan 29.

38.

Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen.

Coyle CM, Weiss LM, Rhodes LV 3rd, Cali A, Takvorian PM, Brown DF, Visvesvara GS, Xiao L, Naktin J, Young E, Gareca M, Colasante G, Wittner M.

N Engl J Med. 2004 Jul 1;351(1):42-7. No abstract available.

39.

Lack of SARS transmission and U.S. SARS case-patient.

Peck AJ, Newbern EC, Feikin DR, Issakbaeva ET, Park BJ, Fehr J, LaMonte AC, Le TP, Burger TL, Rhodes LV 3rd, Weltman A, Erdman D, Ksiazek TG, Lingappa JR; SARS Pennsylvania Case Investigation Team.

Emerg Infect Dis. 2004 Feb;10(2):217-24.

40.

Hantavirus pulmonary syndrome associated with Monongahela virus, Pennsylvania.

Rhodes LV 3rd, Huang C, Sanchez AJ, Nichol ST, Zaki SR, Ksiazek TG, Humphreys JG, Freeman JJ, Knecht KR.

Emerg Infect Dis. 2000 Nov-Dec;6(6):616-21.

41.

Nosocomial herpes simplex virus infection associated with oral endotracheal intubation.

Hanley PJ, Conaway MM, Halstead DC, Rhodes LV 3rd, Reed J 3rd.

Am J Infect Control. 1993 Dec;21(6):310-6.

PMID:
8122803
42.

Rapid assessment of human immunodeficiency virus seroprevalence in a community-based hospital.

Rhodes LV 3rd, Reed JF, Faust LA, Moser K.

Am J Infect Control. 1993 Feb;21(1):9-15.

PMID:
8442525
43.

Impact of human immunodeficiency virus on medical and surgical residents.

Hoffman-Terry M, Rhodes LV 3rd, Reed JF 3rd.

Arch Intern Med. 1992 Sep;152(9):1788-96.

PMID:
1520046
44.

Reduction of catheter-induced infections.

Rhodes LV 3rd.

JAMA. 1982 Aug 20;248(7):830-1. No abstract available.

PMID:
7097940
45.

Isolation of Legionella pneumophila from clinical specimens: salutary effects of lung tissue dilution.

Lattimer GL, Rhodes LV 3rd, Salventi JF, Cepil BR.

Am Rev Respir Dis. 1980 Jul;122(1):101-5.

PMID:
6996548
46.

The Philadelphia epidemic of Legionnaire's disease: clinical, pulmonary, and serologic findings two years later.

Lattimer GL, Rhodes LV 3rd, Salventi JS, Galgon JP, Stonebraker V, Boley S, Haas G.

Ann Intern Med. 1979 Apr;90(4):522-6.

PMID:
373542
47.

Psittacosis or legionnaires' disease?

Lattimer GL, Rhodes LV 3rd.

Lancet. 1979 Mar 31;1(8118):724. No abstract available.

PMID:
85961
48.

Diagnostic specificity of immunoglobulin M (IgM) response in differentiation Legionnaires' disease from psittacosis.

Lattimer GL, Ormsbee RA, Peacock MG, Rhodes LV.

Scand J Infect Dis. 1979;11(4):271-3.

PMID:
394307
49.

Legionnaires' serotypes.

Lattimer GL, Rhodes LV 3rd, Cepil B.

Lancet. 1979 Jan;1(8107):109. No abstract available.

PMID:
84117
50.

Legionnaires' disease. Clinical findings and one-year follow-up.

Lattimer GL, Rhodes LV 3rd.

JAMA. 1978 Sep 8;240(11):1169-71.

PMID:
682292

Supplemental Content

Loading ...
Support Center